Pfizer seeks FDA approval for Xeljanz modified release tablets to treat RA
Pfizer is seeking approval from the US Food and Drug Administration (FDA) for its Xeljanz (tofacitinib citrate) 11mg once-daily modified release tablets to treat moderate-to-severe rheumatoid arthritis (RA) in patients with an inadequate response or …
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Arthritis | Food and Drug Administration (FDA) | Pfizer | Pharmaceuticals | Rheumatoid Arthritis | Rheumatology